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8 Dry powder inhalation of 
colistimethate sodium in cystic fibrosis 
patients using the Twincer® inhaler: 
pulmonary deposition after adapted 
conditions
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The aim of this study was to investigate the effect of an adapted particle size distribution of 
a colistimethate sodium (colistin sulfomethate) dry powder dose inhaled at an intermediate 
inspiratory flow rate with an injection moulded, ready-to-use Twincer® inhaler in order to 
improve lung deposition.
Seven CF patients participated in an open, randomised, cross over, single dose pilot study. 
A 25 mg dry colistimethate sodium dry powder dose was compared with a 158 mg liquid dose 
administered with a Ventstream® nebuliser connected to a PortaNeb® compressor. The dry 
powder dose was well tolerated by the patients. Cmax- and AUC- values after dry powder inhala-
tion were significantly lower compared to jet nebulisation. However, relative bioavailability 
(Fdpi/Fneb) was 3.0 (nominal dose) and 1.4 (actual dose) respectively. The effect of the adapted 
inhalation conditions (larger median particle diameter of 2.1 μm and an inspiratory flow rate 
of 40-45 l/min) on lung deposition could not be established with the pharmacokinetic method 
used and gamma scintigraphy may be of additional value in future studies. The results support 
further research on dry powder inhalation of drugs in CF using the Twincer® inhaler.
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Introduction
Drug targeting to the lungs of CF patients, especially relevant to antibiotics, receives increasing 
attention nowadays. Administration of antibiotics by inhalation improves lung function and 
reduces the number of exacerbations and hospital admissions (Murphy et al., 2004; Flume et 
al., 2007). A majority of CF patients inhale anti-pseudomonal drugs on a daily basis. Accord-
ing to the US Cystic Fibrosis Foundation patient registry, 61.8% of the patients registered in 
2006 were eligible for treatment with an anti-pseudomonal drug for inhalation (tobramycin; 
no data provided for colistimethate sodium (colistin sulfomethate)), corresponding with over 
15000 patients who inhale an anti-pseudomonal drug in the USA every day (Cystic Fibrosis 
Foundation, 2006). The median survival of CF patients has risen from approximately 25 years 
in 1985 (Davis 2006) up to 36.9 years in 2006 (Cystic Fibrosis Foundation, 2006). It is likely that 
inhaled antibiotics will have contributed considerably to this (Frederiksen et al., 1996), given 
the fact that survival is related to (relative) lung function (FEV1) (Kerem et al., 1992) and anti-
pseudomonal drugs have proven to slow down pulmonary deterioration (Ryan et al., 2003). 
However, little is known on the optimal dose (Brochet et al., 2007), optimal particle size and the 
optimal inhalation method in relation to patient characteristics (e.g. age, disease progression) 
for these antibiotics. Furthermore, patient adherence to inhalation therapy is known to be 
poor (Arias Llorente et al., 2008), mainly because of the time and effort needed, twice daily, to 
aerosolize a drug dose and to clean the nebuliser. Therefore, optimisation of, and particularly 
time saving in inhalation therapy for CF patients is likely to further improve current treatment 
results.
Dry powder inhalation of anti-pseudomonal drugs is expected to have several advantages 
over conventional jet nebulisation techniques: patient adherence to inhalation therapy is 
expected to improve whereas the risk of contamination can be eliminated when using a dis-
posable inhaler (this study). Several publications on dry powder inhalation of antibiotics in CF 
have been released recently (Geller et al., 2007; Pilcer et al., 2008). Tobramycin dry powder has 
been inhaled by 90 (Geller et al., 2007) and 9 CF patients (Pilcer et al., 2008) with promising 
results. Dry powder inhalation of the anti-pseudomonal drug colistimethate sodium has been 
described in a study with healthy volunteers and CF patients (Westerman et al., 2007a, 2007b). 
The dry powder drug configuration was well tolerated and appreciated by the CF patients but 
the pharmacokinetic parameters Cmax and AUC after powder inhalation of the 25 mg dose of 
colistimethate sodium from the Twincer® were lower than observed after a 158 mg dose of 
colistimethate sodium using the Ventstream® nebuliser and PortaNeb compressor. However, 
the relative bioavailability of the DPI was 2.7 times higher with reference to the nominal dose.
The clinical pilot study described here is a sequel to the previous patient study in which 
a prototype (machined) inhaler was used under suboptimal conditions for (peripheral) lung 
deposition with respect to powder formulation and inhalation manoeuvre (Westerman et al., 






sodium with an adapted particle size distribution administered with a ready-to-use Twincer® 
at an intermediate inspiratory flow rate. The patients were asked for a breath hold of approxi-
mately 10 seconds following inhalation and lung deposition from dry powder inhalation was 
compared to that from liquid nebulisation (Darquenne et al., 2000; Usmani et al., 2005).
Materials and Methods
Study population
After having given written informed consent, seven CF patients visiting the outpatient clinic 
and on long term treatment with aerosolized colistimethate sodium or tobramycin participated 
in an open, randomised, cross over, single dose pilot study. Demographics of the patients stud-
ied are presented in Table 1. As this study was intended as a pilot study, applying an inhaler 
under development, no special requirements were made on the inclusion (e.g. disease state, 
FEV1) of the participants. Each participant was its own control. Patients were asked to stop their 
regular nebulisation of colistimethate sodium 3 days prior to each study visit. On two separate 
days, the patients inhaled a single dose of colistimethate sodium in a dry powder formulation 
or nebulised the colistimethate sodium solution. The order of treatment was determined by 
randomisation. A minimum of 3 days and a maximum of 10 days were allowed between visits 
1 and 2.
The study was approved of by the regional ethical review board and was performed accord-
ing to the Helsinki declaration. Inclusion criteria were age ≥18 years, clinical diagnosis of CF 
and a positive sweat test or two CF gen mutations, FEV1 >25% of predicted values, routine 
use of nebulised colistimethate sodium, normal kidney function (estimated creatinin clearance 
>50 ml/min), normal liver function (liver enzymes within normal range) and informed consent. 
Exclusion criteria were exacerbation of pulmonary infection (according to criteria by Fuchs et 
al., 1994), intravenous use of colistimethate sodium, colistimethate sodium hypersensitivity, 















P1 F 29 164 55 20.4 58.1 78.9
P2 M 29 170 70 24.2 28.2 58.9
P3 F 37 181 83 25.3 34.2 69.5
P4 F 26 162 58 22.1 47.1 82.1
P5 F 20 154 59 24.8 99.1 104.6
P6 F 29 160 55 21.4 59.8 72.9















*Average of baseline values on day 1 and 2
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pregnancy, suspected pregnancy, breast feeding or any other condition which in the opinion 
of the clinician would make the subject unsuitable for enrolment and treatment with an 
investigational drug within a month prior to enrolment. Each patient inhaled a dry powder 
dose of colistimethate sodium with the Twincer® (University of Groningen, Groningen, The 
Netherlands) and a wet aerosol of colistimethate sodium with the Ventstream® inhaler driven 
by the PortaNeb® compressor (Medic Aid, Romedic, Meerssen, The Netherlands).
Drug and devices
One dry powder dose consisted of 25 mg colistimethate sodium (Ph. Eur quality, sterile, Alp-
harma, Copenhagen, Denmark; 13,200 units/mg), micronised in a jet mill (50 AS, Alpine, Augs-
burg, Germany), plus 4 mg of lactose sweeper crystals (fraction 150–200 μm from Pharmatose 
100 M, DMV International, Veghel, The Netherlands). One dose was administered by a single 
inhalation. The (volume) median diameter (X50) of the colistimethate sodium used in this study 
was 2.1 µm (X10 = 0.9 µm, X90 = 3.8 µm), which is 1.3 times larger than that of the powder used in 
the first colistin DPI study (X10= 0.7 μm, X50 = 1.6 μm, X90 = 3.1 μm)(Westerman et al., 2007b).
Injection moulded Twincer® inhalers were used, slightly adapted compared to the devices 
used in the previous study in the sense that they were designed with one dose compartment 
in which a blister was placed. PVC-coated aluminium blisters were supplied by Tommy Nielsen, 
Esbjerg, Denmark and sealed with a peelable lid after filling one dose for inhalation with a Uni-
versal 301 FS blister machine (Tommy Nielsen). The dry powder doses were weighed in by hand 
into the blisters according to good manufacturing practice (GMP) guidelines and subsequently 
the inhaler parts were assembled using an ultrasonic welding machine (Rinco Ultrasonics, 
Switzerland).
Patients were instructed to inhale at a moderate flow rate (40-45 L/min) and to hold their 
breath subsequently for 10 seconds with a minimum of 7 seconds. Breath hold periods 
were timed by the investigator using a stopwatch. Prior to inhalation, patients were given 
the opportunity to practise the inhalation manoeuvre by inhaling though an instrumented 
dummy-Twincer®. All inhalation flow curves were recorded and as soon as a series of consis-
tent manoeuvres was obtained, the colistimethate sodium dry powder inhaler was given to 
the patient for administration of the drug. In case of a visually incomplete discharge of the 
dose from the blister, the patient was asked to repeat the inhalation procedure. Patients were 
observed and asked for adverse effects after inhalation and during the study day. From the 
consistent flow recordings the (mean) peak, average flow rate and the inhaled volume were 
computed.
A dose of 2 million units or 158 mg of colistimethate sodium (Ph. Eur quality, sterile, Alpharma, 
Copenhagen, Denmark; approx. 13,200 units/mg) was dissolved in 6 ml of sterile isotonic saline 
by the hospital pharmacy shortly before nebulisation and was transferred into the Ventstream® 
nebuliser cup in two portions. An expiration filter was connected to the nebuliser. Patients were 






The drug output (actual dose) of the inhalation device was calculated by subtracting the 
retained mass of drug in the device from the nominal dose originally put in the device.
Drug retention was determined by weighing the Twincer® before and after inhalation (ana-
lytical balance, Mettler-Toledo, The Netherlands) and by using a modified Lowry protein assay 
for the Ventstream® nebuliser (Lowry et al., 1951).
Study parameters
Pulmonary function tests (FEV1, FVC) were performed before, 5 and 30 min after inhalation or 
nebulisation, using a calibrated Masterlab pneumotachograph (Jaeger, Würzburg, Germany). 
The patients received instructions to carry out lung function tests. Measured lung function 
parameters were normalized to the reference values proposed by the European Community 
for Coal and Steel (Quanjer et al., 1993) and the results were related to the predicted baseline 
values for each patient. Any change (%) in lung function after drug inhalation was expressed 
relative to the patient’s actual baseline values, and is therefore not related to the predicted 
baseline values. A reduction in FEV1 of 10% or more was considered to be a clinically relevant 
proof of airway reactivity.
Venous blood sampling, storage and sample analysis of serum sampling was performed 
identically to the former study (Westerman et al., 2007b). Similarly, no interference of the assay 
by co-medication of the patients was observed. Individual pharmacokinetic profiles were cal-
culated based on the output/actual dose for each patient, using the method described earlier 
(Westerman et al., 2007b) while a new population pharmacokinetic model was made based 
upon data of the 7 patients. The results have been used as an indirect reflection of peripheral 
pulmonary deposition.
The same questionnaire that has been used previously (Westerman et al., 2007b) was applied 
to get an impression of the patient’s experience with the dry powder inhaler compared to wet 
nebulisation at home. Answers were given on a 6 scale scoring system (none (1) - severe (6) or 
very bad (1) – excellent (6)).
Statistical analysis
The data were tested for a normal distribution using the Kolmogorov-Smirnov test. The Student’s 
paired t-test for changes within groups was applied to compare both inhalation methods. Data 
are expressed by means and confidence intervals. The significance level was set at p=0.05.
Results
Pulmonary function tests
Both colistimethate sodium doses (either from Twincer® or from Ventstream®) were well toler-
ated by all patients. Patient 1 suppressed a cough reflex during inhalation of the dry powder 
which is likely to have negatively influenced the output of the inhaler (15.2 mg).
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Lung function tests after dry powder inhalation showed no abnormalities. See Table 2. Patient 
2 and 4 experienced chest tightness both after dry powder inhalation and nebulisation (see 
results Questionnaire). No airway narrowing (fall in FEV1 > 10%) was observed after dry powder 
inhalation. Nebulisation caused a fall in FEV1 of 13.5% in patient 7 shortly after nebulisation, which 
improved to a decrease of 9.7% at t = 30 min. Patients 3 and 4 had a post-nebulisation fall in FVC 
of 10.5% and 14.8% respectively, which after 30 minutes was unchanged for patient 3 (12.5%) 
but improved for patient 4. Mean inspiratory flow rate was 35.3 L/min (range 33.7-37.3 L/min, C.V. 
4%) and peak inspiratory flow rate 43.9 L/min (range 40.6-48.8 L/min, C.V. 6%), corresponding 
with a calculated inhaled volume of 1.8 L (range 0.9-2.4 L, C.V. 28%). No correlations were found 
between mean inspiratory flow rate, peak inspiratory flow rate, inhaled volume and AUC or Cmax. 
All patients were able to hold their breath for at least 7 seconds after inhaling the dry powder.
Colistimethate sodium output and pharmacokinetics
The retained drug mass in the DPI, calculated with reference to the nominal dose, was 25.5% 
(range 20.2-38.0%) which is a substantial increase compared to the 7.6% (range 3.0-22.0%) in 
the previous study. The residual volume in the Ventstream® after nebulisation was 33.2% (range 
20.3-47.5%) which is lower than the approximately 40% with the same nebuliser-compressor 
combination observed in other studies (Le Brun et al., 2002; Westerman et al., 2007. However, 
Table 2: Individual FEV1 and FVC-values after dry powder inhalation and nebulisation of colistimethate 
sodium
FEV1
DPI at t=0 min, 
(% predicted)
DPI at t=5 min, 
relative to 
baseline (%)
DPI at t=30 
min, relative to 
baseline (%)
Neb. at t=0 
min, (% predicted)
Neb. at t=5 
min, relative to 
baseline (%)
Neb. at t=30 
min, relative to 
baseline (%)
patient 1 1.84 (58) -2.7% -0.5% 1.83 (58) -7.1% -5.5%
patient 2 1.11 (28) -8.1% -9.0% 1.14 (29) -6.1% -2.6%
patient 3 1.18 (33) 3.4% 5.9% 1.30 (36) -6.2% -5.4%
patient 4 1.47 (47) -6.8% -6.8% 1.48 (47) -0.7% 4.7%
patient 5 2.85 (100) 3.2% 3.9% 2.81 (98) -6.1% 2.1%
patient 6 1.74 (58) -3.5% -5.2% 1.84 (61) -2.2% -2.2%
patient 7 2.42 (57) -3.3% -1.7% 2.38 (56) -13.5% -9.7%
FVC
patient 1 2.87 (79) -1.4% 1.1% 2.84 (79) -0.70% 0.0%
patient 2 2.79 (59) -5.7% -6.5% 2.74 (58) -9.9% -7.7%
patient 3 2.92 (70) 1.4% -1.0% 2.87 (69) -10.5% -12.5%
patient 4 2.79 (78) -4.7% 1.8% 3.10 (86) -14.8% -4.5%
patient 5 3.44 (105) 2.9% 1.2% 3.42 (104) -6.1% -1.5%
patient 6 2.49 (72) -2.4% -2.0% 2.53 (73) -2.8% -0.8%
patient 7 3.92 (79) -0.5% -2.3% 3.91 (79) -9.5% -7.7%
Baseline values in liters (% predicted)






data from colistimethate sodium measurements in the expiration filter (data not shown) 
indicated a higher collected amount in this study compared to the previous study. As a result, 
the estimated inhaled fraction will have been lower which is an explanation for the lower Cmax 
and AUC found. Despite this, the relative bioavailability based on the output (actual dose) is 
comparable to that calculated in the previous study (Fdpi/Fneb is 1.4), whereas based on the 
nominal dose it is even higher (Fdpi/Fneb is 3.0). These and other pharmacokinetic parameters 
are displayed in Table 3. Also in this study the differences between the AUC0-4, Cmax and tmax 
between the two inhalations were statistically significant, while t1/2 and CL/F, obviously, were 
not. Variation in PK parameters, expressed in C.V., was large. Figure 1 displays the individual 
fitted serum concentration time curves after inhalation.
Questionnaire
Four patients were very positive about the inhaler concept (score 6), because of the ease of 
use, including not having to prepare the drug prior to administration and to clean the inhaler 
afterwards, better hygiene and an expected improvement in adherence to inhalation treatment. 
One patient was positive but with a lower score (score 5) because she thought it difficult to 
inhale at the prescribed inhalation flow and two patients were only moderately content due to 
powder particle retention in the mouth and a strong taste or a cough reflex during inhalation. 
These patients therefore scored 3 with respect to adverse effects. One patient scored 2 as an 
adverse effect because of a dry, itching throat and two other patients experienced some chest 
Table 3: Colistimethate sodium dry powder inhalation in patients: pharmacokinetic results (n=7)
Mean DPI 95% C.I. C.V. (%) Mean Neb 95% C.I. C.V. (%) p-value
Actual dose (mg) 18.6 18.2-19.1 9 55.7 51.3-60.1 28
AUC0-4 (h.μg/L) 182.5 117.7-247.3 48 380.3 334.5-426.1 43 0.02*
Cmax (μg/L) 62.7 38.4-86.9 52 122.5 107.7-137.3 43 0.02*
tmax (h) 0.74 0.70-0.79 9 1.16 0.74-1.59 13 <0.001*
t1/2,el (h) 2.9 2.8-3.0 10 2.8 2.4-3.3 6 0.50
Cl/F (L/h/kg) 1.1 1.0-1.2 34 1.5 1.4-1.7 42 0.09
FDPI/Fneb 1.4 0.4-2.4 30
Actual dose nominal dose minus remainder of colistin in inhalation device after inhalation.
AUC0-4  area under the curve from 0 to 4 h.
Cmax  maximum plasma concentration
tmax  time to maximum concentration
t1/2,el  terminal half-life
Cl/F   clearance following pulmonary administration
FDPI/Fneb  relative bioavailability, calculated on actual dose
C.I.  confidence interval
C.V.  coefficient of variation
*  statistically significant
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tightness for which a rating 2 was given. Two patients did not experience any adverse effect at 
all. The adverse effects appeared within 10 minutes after inhalation with the DPI or nebulisation 
with the jet nebuliser. Patient 2 and 4 experienced chest tightness after dry powder inhalation, 
but their fall in FEV1 was within 10% from the baseline. Five patients went through a period of 
chest tightness after jet nebulisation, of which patient 2 and 4 indicated that this effect was more 
severe than after dry powder inhalation. Four patients felt a cough reflex, three of them coughed 
during breath hold, which may possibly have had a negative influence on the lung dose. Two 
patients thought the cough reflex was generated by the air flow through the nebuliser. Four 
patients mentioned the taste of the dry powder, of which two patients disliked this taste.
Discussion
This study was conducted with the objective to improve lung deposition of inhaled colis-
timethate sodium with the Twincer® dry powder inhaler in CF patients. We have investigated 
the influence of a slightly larger median particle diameter in combination with a lower inspira-
tory flow rate compared to a previous study, expecting that this would yield a higher (periph-
eral) deposition. We indeed obtained a slightly higher relative bioavailability (Fdpi/Fneb) of 3.0 
(compared to 2.7 in the previous study) based on the nominal dose and an equivalent relative 
bioavailability of 1.4 based on the actual dose (Westerman et al., 2007). Obviously, the small 
number of participants makes it impossible to draw distinct conclusions from our results, but 
the data are useful in further dry powder development of drugs in CF treatment.
In this study four modifications to the previous study have been introduced: a dry powder 
formulation with a slightly larger median particle diameter, an intermediate inhalation peak 
flow rate, a longer breath-hold and an injection moulded Twincer® inhaler.
The median particle diameter in this study was 2.1 μm compared to 1.6 μm in the previous 
study. Although these proportions are indicative for the two powder formulations that have been 
used, it is actually the combination of the median particle diameter and particle size distribution 
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that should be considered when estimating and calculating powder behaviour in the lung. How-
ever, these calculations are beyond the scope of this study. The larger median particle diameter 
was introduced to enlarge lung deposition primarily by improving sedimentation. The inhalation 
peak flow rate in this study was 43.9 l/min (was: 67.9 l/min). An intermediate flow rate is expected 
to reduce impaction of the aerosolized dry particles in the oropharynx and to result in an effective 
lung deposition at the same time. The longer breath hold was introduced to give the aerosol 
more time for deposition by sedimentation in the bronchiolal and alveolar regions of the lung. 
Finally, the injection moulded Twincer® inhaler is a ready-to-use device which is able to effectively 
disperse 25 mg in one inhalation manoeuvre. The Twincer® used in the previous study was a pro-
totype which was filled and assembled by hand on each study day. This model was constructed 
with two dose compartments which contained 12.5 mg of colistimethate sodium each.
The results, expressed as relative bioavailabilities, were similar to the results in the previous 
study and have been obtained by a pharmacokinetic analysis. Another, theoretical method for 
estimating the obtained lung dose from inhalers is to calculate the impaction parameter, that 
incorporates the particle aerodynamic diameter or geometric diameter and the average airflow 
rate and, depending on the equation used, the particle density (DeHaan and Finlay 2004). The 
impaction parameter is often used to predict drug loss in the oral cavity and oropharynx. 
Applying this equation on the results obtained in the previous and the current study results 
in comparable impaction parameters of 4346 and 4840 μm2cm3s-1, corresponding with a loss 
of approximately 9.1% and 10.1% in the oral cavity and oropharynx respectively. Therefore, 
the fraction of the 25 mg colistimethate sodium that was able to enter the lungs has been 
equal in both dry powder inhalation studies, and it is likely that inertial deposition in the upper 
respiratory tract will have been comparable as well. Theoretically, the advantage of the inhaler 
in the current study is therefore to be found in a higher sedimentation velocity in central and 
peripheral airways. It is to be expected that a higher lung deposition has been obtained in 
this study, as terminal velocity increases with a larger particle diameter and more time has 
been created for sedimentation in lung generations 11-23 because of an extended breath hold 
(Usmani et al., 2005). Unfortunately, no convincing evidence for this theoretical advantage has 
been found with the pharmacokinetic method used for determining lung deposition (relative 
bioavailability). Gamma scintigraphic methods can support further studies, as regional differ-
ences in deposition cannot be measured with PK method (Chrystyn 2001).
Among other (unknown) factors, interpatient variability will have influenced the results in 
this pilot study. This variability is well known in lung deposition studies in CF patients and is 
especially relevant in studies with a small number of subjects. This variability is made up by 
variation in inhalation technique and variation in lung deposition due to different stages of 
disease progression. In this study the coefficient of variation of Cmax and AUC after dry powder 
inhalation (52% and 48% respectively) is larger compared to jet nebulisation (43% and 43% 
respectively). However, this variation is predominantly caused by patient 5. Excluding this patient 
results in a C.V. of 24% and 23% for Cmax and AUC after dry powder inhalation respectively, 
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and this suggests that nebulisation is less reproducible than dry powder inhalation. Without 
the data of patient 5, the relative bioavailability changes slightly in favour of wet nebulisation, 
without changing the observed trends and significance in pharmacokinetic parameters.
The interpatient variability is a weak point in comparative study designs in CF as is jet nebu-
lisation as reference treatment which is known for its variable results. It is a paradox, as clinically 
administration of colistimethate sodium by jet nebulisation is still the gold standard. The value 
of comparing relative bioavailabilities within this study or between the previous study and this 
study is therefore questionable, as the results are guided by patient variability.
The new inhaler was appreciated by the patients and the dry powder drug dose was well toler-
ated. Airway reactivity (FEV1) was measured in one patient after wet nebulisation but not after 
dry powder inhalation. Post-nebulisation decrease in FVC values was observed in two patients, 
but not after dry powder inhalation. Similar results were obtained in the previous study, and 
further research is needed to elucidate whether these effects are a result of the physical form of 
the inhaled drug (aerosol in droplets versus powder particles), local high drug concentrations 
in the proximal lung and/or the absolute amount of drug entering the target area in the lung, 
in relation to the disease state of the particular patient.
The residual mass in the DPI was higher than previously observed, which can be attributed 
to the introduction of a large blister to the design of the injection moulded Twincer®. The blister 
used for this colistimethate sodium study was designed to contain 12.5 mg of spray-freeze dried 
powder which has a large volume due to its high porosity. The same blister may contain 60 mg 
of colistimethate sodium and as a result of only partially filling the blister (25 mg), considerable 
losses by adhesion onto the blister wall and blister seal occurred during transport and handling 
of the Twincer® devices. Without the blister seal in vitro data indicate only marginal drug loss 
within 1% of the nominal dose for payloads of 5-50 mg (data not shown).
In conclusion, colistimethate sodium dry powder inhalation with the Twincer® inhaler is 
efficient and well tolerated by CF patients. The influence of altered inhalation conditions on 
lung deposition could not be established with the pharmacokinetic method used. Gamma 
scintigraphy may be of additional value in future studies. The results support further research 
on dry powder inhalation of drugs in CF using the Twincer® inhaler.
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